|1.||Saraiva, Juliana: 4 articles (04/2013 - 01/2005)|
|2.||Esperandim, Viviane Rodrigues: 3 articles (04/2013 - 08/2010)|
|3.||de Albuquerque, Sérgio: 3 articles (04/2013 - 08/2010)|
|4.||Bastos, Jairo Kenupp: 3 articles (04/2013 - 08/2010)|
|5.||da Silva Ferreira, Daniele: 3 articles (04/2013 - 08/2010)|
|6.||Cunha, Wilson Roberto: 2 articles (04/2013 - 01/2013)|
|7.||Bastos, J K: 2 articles (03/2004 - 05/2001)|
|8.||e Silva, Márcio Luis Andrade: 1 article (04/2013)|
|9.||Rezende, Karen Cristina Souza: 1 article (04/2013)|
|10.||Sousa Rezende, Karen Cristina: 1 article (01/2013)|
05/01/2001 - "Cubebin, a dibenzylbutyrolactone lignan isolated from the crude hexane extract of the leaves of Zanthoxyllum naranjillo, showed a significant anti-inflammatory activity by using the paw edema induced by carrageenin in rats, but did not provide a significant reduction in the cell migration for the acute carrageenin-induced inflammatory reaction in the peritoneal cavity of rats. "
03/01/2004 - "The (-)-o-benzyl cubebin showed a low anti-inflammatory effect (16.2%) in relation to cubebin (57%) and indomethacin (77%) in the carrageenin-induced paw edema in rats, but on the other hand it was more effective (80%) than (-)-cubebin (41%) in inhibiting acetic acid-induced writhing in mice, producing dose-response correlation with doses of 10, 20 and 40 mg/kg, respectively. "
|2.||Chagas Disease (American Trypanosomiasis)
01/01/2013 - "Therefore, (-)-cubebin and (-)-hinokinin are promising therapeutic agents and could be used in future clinical studies concerning treatment of the Chagas disease. "
08/01/2010 - "The reduction of parasitism tissue upon treatment with two lignano lactones, namely (-)- cubebin (CUB) and (-)-hinokinin (HNK), was evaluated in the chronic phase of Chagas' disease by quantifying the enzyme beta-galactosidase expressed by the CL B5 clone strain of Trypanosoma cruzi. "
01/17/2005 - "Five (-)-cubebin derivative compounds, (-)-O-acetyl cubebin (3), (-)-O-benzyl cubebin (4), (-)-O-(N,N-dimethylaminoethyl)-cubebin (5), (-)-hinokinin (6) and (-)-6,6'-dinitrohinokinin (7), previously synthesised by our research group, were evaluated on in vitro assay against free amastigote forms of Trypanosoma cruzi, the asogic agent of Chagas' disease. "
01/01/2013 - "We determine whether (-)-cubebin and (-)-hinokinin could be used as alternative drugs for the treatment of parasitic infections by Trypanosoma cruzi. "
04/01/2013 - "In this context, this study aims to evaluate the in vivo therapeutic activity of dibenzylbutyrolactone lignans (-)-cubebin and (-)-hinokinin during the acute phase of infection by T. "
07/15/2007 - "(-)-Cubebin showed a melanogenesis stimulation activity in a concentration-dependent manner in murine B16 melanoma cells without any significant effects on cell proliferation. "
07/15/2007 - "Mechanism of the melanogenesis stimulation activity of (-)-cubebin in murine B16 melanoma cells."
|5.||Acetic Acid (Vinegar)